RC
NBIX icon

RegentAtlantic Capital’s Neurocrine Biosciences NBIX Stock Holding History

RegentAtlantic Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100
Closed -$2.23K – 705
2014
Q4 		$2.23K Buy
+100
New +$1.9K ﹤0.01% 1114

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

RegentAtlantic Capital's NBIX Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2015, closing a stake of 100 shares — an estimated $2.23K sold.

RegentAtlantic Capital first reported a position in NBIX in Q4 2014 and held it in 1 quarter. The position peaked at $2.23K in Q4 2014. 174 funds tracked by Wall St. Rank hold NBIX as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Neurocrine Biosciences position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 100 Neurocrine Biosciences shares in Q1 2015, an estimated $2.23K.
  • RegentAtlantic Capital first reported a position in Neurocrine Biosciences in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Neurocrine Biosciences position peaked at $2.23K in Q4 2014.
  • 174 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.